Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam.

Lam WJ, Bhowmick T, Gross A, Vanschooneveld TC, Weinstein MP.

Ann Pharmacother. 2013 Jun;47(6):886-91. doi: 10.1345/aph.1R721. Epub 2013 May 28. Review.

PMID:
23715072
2.

Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.

Mah GT, Mabasa VH, Chow I, Ensom MH.

Ann Pharmacother. 2012 Feb;46(2):265-75. doi: 10.1345/aph.1Q378. Epub 2012 Jan 24. Review.

PMID:
22274145
3.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

4.

Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.

Xamplas RC, Itokazu GS, Glowacki RC, Grasso AE, Caquelin C, Schwartz DN.

Am J Health Syst Pharm. 2010 Apr 15;67(8):622-8. doi: 10.2146/ajhp090447.

PMID:
20360589
5.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group.

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
6.

Development and implementation of a piperacillin-tazobactam extended infusion guideline.

Heinrich LS, Tokumaru S, Clark NM, Garofalo J, Paek JL, Grim SA.

J Pharm Pract. 2011 Dec;24(6):571-6. doi: 10.1177/0897190011406984.

PMID:
21676847
7.

Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.

D'Agostino C, Rhodes NJ, Skoglund E, Roberts JA, Scheetz MH.

J Infect Chemother. 2015 Oct;21(10):742-6. doi: 10.1016/j.jiac.2015.05.010. Epub 2015 Jun 9.

PMID:
26143049
8.

Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.

Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.

J Antimicrob Chemother. 2014 Jan;69(1):176-9. doi: 10.1093/jac/dkt300. Epub 2013 Jul 18.

9.

Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.

Lee GC, Liou H, Yee R, Quan CF, Neldner K.

Clin Ther. 2012 Dec;34(12):2297-300. doi: 10.1016/j.clinthera.2012.11.005. Epub 2012 Nov 27.

PMID:
23195962
10.

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Kim A, Sutherland CA, Kuti JL, Nicolau DP.

Pharmacotherapy. 2007 Nov;27(11):1490-7.

PMID:
17963458
11.

Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.

Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.

Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.

PMID:
19809009
12.

Rationale and evidence for extended infusion of piperacillin-tazobactam.

Kaufman SE, Donnell RW, Hickey WS.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1521-6. doi: 10.2146/ajhp100694. Review.

PMID:
21817083
13.

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.

Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review.

15.

Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.

Yusuf E, Spapen H, Piérard D.

J Crit Care. 2014 Dec;29(6):1089-95. doi: 10.1016/j.jcrc.2014.07.033. Epub 2014 Aug 7. Review.

PMID:
25179412
16.

Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.

Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.

Int J Antimicrob Agents. 2013 Jan;41(1):52-6. doi: 10.1016/j.ijantimicag.2012.09.004. Epub 2012 Dec 8.

PMID:
23228881
17.

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC, De Waele JJ.

Crit Care. 2013 May 3;17(3):R84. doi: 10.1186/cc12705.

18.

Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.

McCormick H, Tomaka N, Baggett S, Heierman T, LaFosse J, Gilbert S, Imhof K.

Am J Health Syst Pharm. 2015 Jun 1;72(11 Suppl 1):S25-30. doi: 10.2146/sp150007.

PMID:
25991590
19.

Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.

J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.

20.

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.

Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, Teppler H; Protocol 023 Study Group.

Infect Dis Obstet Gynecol. 2003;11(1):27-37.

Items per page

Supplemental Content

Write to the Help Desk